Lupin receives EIR from USFDA for Pithampur facility
April 06, 2018 | Friday | News
The inspection was conducted in July 2017
Drug Pharmaceutical Company has received establishment investigation report (EIR) from the United States Food and Drug Administration (US FDA) for the successful inspection of Pithampur, Unit 1 manufacturing facility in Madhya Pradesh.
The inspection was conducted in July 2017.
USFDA gives EIR on closure of inspection of an establishment that is the subject of an FDA or FDA-contracted inspection.
"The successful outcome of this inspection is encouraging, and further validates our commitment to meeting global manufacturing standards. We are committed to upholding the highest levels of quality and compliance standards across all our facilities,” said Nilesh Gupta, Managing Director, Lupin.
